Non-Oral Drug Delivery Strategies: From Early Diagnosis to Advanced Treatments

Chairpeople:

Claudia Trenkwalder,¹ Werner Poewe²

Speakers:

Werner Poewe,² Fabrizio Stocchi,³ Stuart H. Isaacson⁴

1. University Medical Centre of Göttingen, Göttingen; and Paracelsus Elena Klinik, Center of Parkinsonism and Movement Disorders, Kassel, Germany
2. Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
3. Institute of Research and Medical Care, IRCCS San Raffaele, Rome, Italy
4. Florida International University, Herbert Wertheim College School of Medicine, Miami; Parkinson’s Disease and Movement Disorders Center of Boca Raton, Boca Raton; and Marcus Neuroscience Institute, Boca Raton Regional Hospital, Boca Raton, Florida, USA

Disclosure:

C. Trenkwalder has received personal fees for advisory boards from Mundipharma, UCB, Vifor Pharma, Britannia Pharmaceuticals, and Novartis; she has also received payments for lectures from UCB, AstraZeneca, and Desitin; and has received royalties from Schattauer Verlag. W. Poewe has received personal fees from Britannia for consultancy and lecture fees in relation to clinical drug development programmes for Parkinson’s disease (PD); he has also received personal fees from AbbVie, AstraZeneca, Britannia, Lundbeck, Teva, Novartis, GSK, Boehringer-Ingelheim, UCB, Orion Pharma, Zambon, and Merz Pharmaceuticals for consultancy and lecture fees in relation to clinical drug development programmes for PD, outside of the submitted work; and has received royalties from Thieme, Wiley Blackwell, and Oxford University Press. F. Stocchi has received honoraria for participation in scientific advisory boards for GSK, Teva, Boehringer Ingelheim, Newron, Merck Serono, Novartis, Lundbeck, Impax, Schering-Plough, MSD, and UCB; and has received speaker fees for educational lectures for GSK, Teva, Boehringer Ingelheim, Merck Serono, Novartis, Lundbeck, UCB, and Britannia. S. H. Isaacson has received honoraria for CME activities, research grants and/or consultant and promotional speaker fees from AbbVie, Acadia, Adamas, Addex, Allergan, Allon, AstraZeneca, Biotie, Britannia, Chelsea, Civitas, Eisai, GE, GSK, Impax, Ipsen, Kyowa, Lilly, Merck Schering-Plough, Medtronics, Merz, Michael J. Fox Foundation, Novartis, Neurocrine, National Institutes of Health (NIH), Novartis, Orion, Parkinson Study Group, Phytopharm, Purdue, Roche, Santhera, Serono, Shire, Teva, UCB, and US World Meds.

Acknowledgements:

Writing assistance was provided by Dr Karen Wolstencroft, Helen Lawn Associates PR Limited.

Support:

This symposium and the publication of this article was funded by Britannia Pharmaceuticals Limited. The views and opinions expressed are those of the authors and not necessarily of Britannia Pharmaceuticals Limited.

Citation:

EMJ Neurol. 2015;3[1]:40-49. DOI/10.33590/emjneurol/10314470. https://doi.org/10.33590/emjneurol/10314470.

Keywords:

EAN 2015, European Academy of Neurology

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.